MX371198B - Terapia antidiabetica vasoprotectora y cardioprotectora. - Google Patents
Terapia antidiabetica vasoprotectora y cardioprotectora.Info
- Publication number
- MX371198B MX371198B MX2016005628A MX2016005628A MX371198B MX 371198 B MX371198 B MX 371198B MX 2016005628 A MX2016005628 A MX 2016005628A MX 2016005628 A MX2016005628 A MX 2016005628A MX 371198 B MX371198 B MX 371198B
- Authority
- MX
- Mexico
- Prior art keywords
- vasoprotective
- antidiabetic therapy
- inhibitors
- cardioprotective
- dpp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a ciertos inhibidores de DPP-4 para tratar y/o prevenir el estrés oxidativo, estrés vascular y/o disfunción endotelial así como al uso de dichos inhibidores de DPP-4 en el tratamiento y/o prevención de pacientes diabéticos o no diabéticos, incluyendo grupos de pacientes con riesgo de enfermedad cardiovascular y/o renal.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10191261 | 2010-11-15 | ||
US41554510P | 2010-11-19 | 2010-11-19 | |
US42140010P | 2010-12-09 | 2010-12-09 | |
EP11168317 | 2011-05-31 | ||
US201161492391P | 2011-06-02 | 2011-06-02 | |
EP11170992 | 2011-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX371198B true MX371198B (es) | 2020-01-22 |
Family
ID=65948805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005628A MX371198B (es) | 2010-11-15 | 2011-11-15 | Terapia antidiabetica vasoprotectora y cardioprotectora. |
Country Status (5)
Country | Link |
---|---|
JP (2) | JP7227107B2 (es) |
KR (1) | KR102117282B1 (es) |
ES (1) | ES2777890T3 (es) |
MX (1) | MX371198B (es) |
PT (1) | PT2640371T (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
CA2496249C (en) * | 2002-08-21 | 2012-01-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
AR074990A1 (es) * | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
NZ594044A (en) | 2009-02-13 | 2014-08-29 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
EP2424507A4 (en) | 2009-04-27 | 2012-10-24 | Revalesio Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INSULIN AND DIABETES RESISTANCE |
-
2011
- 2011-11-15 PT PT117876557T patent/PT2640371T/pt unknown
- 2011-11-15 ES ES11787655T patent/ES2777890T3/es active Active
- 2011-11-15 KR KR1020197007010A patent/KR102117282B1/ko active IP Right Review Request
- 2011-11-15 MX MX2016005628A patent/MX371198B/es unknown
-
2019
- 2019-09-05 JP JP2019161690A patent/JP7227107B2/ja active Active
-
2021
- 2021-09-10 JP JP2021147541A patent/JP2021185204A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020002159A (ja) | 2020-01-09 |
PT2640371T (pt) | 2020-04-17 |
KR20190028571A (ko) | 2019-03-18 |
JP2021185204A (ja) | 2021-12-09 |
ES2777890T3 (es) | 2020-08-06 |
JP7227107B2 (ja) | 2023-02-21 |
KR102117282B1 (ko) | 2020-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX340515B (es) | Terapia antidiabética vasoprotectora y cardioprotectora. | |
MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
MY156243A (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
TN2011000466A1 (en) | Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof | |
WO2010065671A3 (en) | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf | |
EP2493464A4 (en) | METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS | |
PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
WO2009045356A3 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
IL206563A (en) | A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer | |
MX2020013740A (es) | Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular. | |
MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
WO2010071826A3 (en) | Methods for treating osteoclast-related disease, compounds and compositions thereof | |
EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
MX2011012310A (es) | Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen). | |
MA32416B1 (fr) | 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation | |
MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
MX371198B (es) | Terapia antidiabetica vasoprotectora y cardioprotectora. | |
MY166065A (en) | Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases | |
NZ702666A (en) | A method of weight reduction | |
WO2012099999A3 (en) | Methods and compositions for inducing weight loss | |
TN2011000060A1 (en) | Treatment for diabetes in patients inappropriate for metformin therapy |